The Neuropeptide Semax Binds Toxic Copper and Protects Brain Cells From Metal-Induced Damage
Semax, a synthetic brain-protective peptide derived from ACTH, forms stable complexes with copper(II) ions and significantly reduces copper-induced toxicity in neuronal and endothelial cell lines.
Quick Facts
What This Study Found
Semax (Met-Glu-His-Phe-Pro-Gly-Pro), an ACTH4-10 analog with a C-terminal Pro-Gly-Pro extension, demonstrated:
- Formation of three distinct copper(II) complex species
- At pH 5 and above, the predominant species [CuLH-2]2- features 4-nitrogen planar coordination around copper
- Two minor species [CuL] and [CuLH-1]- coexist at pH 3.6-5
- Significant reduction of copper-induced cytotoxicity in:
- SH-SY5Y neuroblastoma cells (brain neuron model)
- RBE4 endothelial cells (blood-brain barrier model)
- Protection assessed by MTT cell viability assay
This reveals that Semax’s neuroprotective activity may partly operate through metal ion chelation rather than solely through receptor-mediated signaling.
Key Numbers
How They Did This
Copper(II) binding was characterized using equilibrium potentiometry and electron spin resonance (ESR) spectroscopy across a pH range. Complex speciation was determined as a function of pH. Neuroprotective activity was tested using MTT cell viability assays on SH-SY5Y neuroblastoma cells (modeling brain neurons) and RBE4 endothelial cells (modeling the blood-brain barrier), comparing copper toxicity in the presence and absence of Semax.
Why This Research Matters
Metal ion dysregulation — particularly excess copper and zinc — is increasingly recognized as a driver of Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Semax is already approved in Russia for stroke and cognitive enhancement, and has a strong safety profile. This study reveals that Semax can serve double duty: providing cognitive benefits through its known neuroprotective signaling while also directly neutralizing toxic metal ions in the brain. This dual mechanism makes it a particularly attractive candidate for neurodegeneration research.
The Bigger Picture
Metal chelation therapy for neurodegenerative diseases has long been explored, but finding chelators that can cross the blood-brain barrier and are safe for long-term use has been challenging. Semax is uniquely positioned: it’s a small peptide with known brain penetration (administered intranasally), established safety in clinical use, and now demonstrated metal-binding capability. This study bridges peptide neuropharmacology with bioinorganic chemistry, suggesting that the most effective neuroprotective strategies may need to address both signaling and metal homeostasis.
What This Study Doesn't Tell Us
This is an in vitro study using cell lines — protection in cultured cells may not translate to in vivo neuroprotection. The copper concentrations used in toxicity assays may not reflect physiological brain copper levels. The study focused on copper only; interactions with other relevant metals (zinc, iron) were not tested. Whether Semax reaches brain copper pools at sufficient concentrations after clinical administration is unknown. The study does not determine whether metal binding or receptor signaling is the primary mechanism of Semax’s known clinical benefits.
Questions This Raises
- ?Does Semax’s copper-binding ability contribute to its clinical neuroprotective effects in stroke patients?
- ?Could Semax be effective in Alzheimer’s disease, where copper dysregulation at amyloid plaques is a recognized pathological feature?
- ?How do Semax-copper complexes interact with other brain proteins, and could they have additional biological activities?
Trust & Context
- Key Stat:
- Dual neuroprotection mechanism Semax protects brain cells both through its known receptor-mediated signaling and — as this study reveals — by directly binding and neutralizing toxic copper(II) ions in a stable 4-nitrogen planar coordination complex.
- Evidence Grade:
- This is an in vitro biophysical and cell biology study characterizing metal binding and cytoprotection. While it reveals an important new mechanism for a clinically used peptide, the findings require in vivo validation. Semax is approved in Russia but has limited clinical evidence by Western regulatory standards.
- Study Age:
- Published in 2015, this study is about a decade old. However, the bioinorganic chemistry of Semax-copper interactions and the relevance of metal chelation in neurodegeneration remain active research areas.
- Original Title:
- Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity.
- Published In:
- Journal of inorganic biochemistry, 142, 39-46 (2015)
- Authors:
- Tabbì, Giovanni, Magrì, Antonio, Giuffrida, Alessandro, Lanza, Valeria, Pappalardo, Giuseppe, Naletova, Irina, Nicoletti, Vincenzo Giuseppe, Attanasio, Francesco, Rizzarelli, Enrico
- Database ID:
- RPEP-02805
Evidence Hierarchy
Frequently Asked Questions
What is Semax and what is it used for?
Semax is a synthetic peptide based on a fragment of ACTH (adrenocorticotropic hormone, a stress-response hormone). It’s approved in Russia as a nasal spray for treating stroke, cognitive impairment, and enhancing mental performance. It’s known to protect brain cells and improve learning. This study reveals an additional mechanism: Semax can bind toxic copper ions, which accumulate in the brain during neurodegenerative diseases.
How does copper damage the brain?
The brain naturally concentrates metal ions, including copper, which are essential for normal nerve function. However, when copper levels become dysregulated — as occurs in Alzheimer’s disease, Parkinson’s disease, and Wilson’s disease — excess free copper generates harmful reactive oxygen species that damage and kill brain cells. By binding copper into stable, non-toxic complexes, Semax can neutralize this damage, adding to its neuroprotective toolkit.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02805APA
Tabbì, Giovanni; Magrì, Antonio; Giuffrida, Alessandro; Lanza, Valeria; Pappalardo, Giuseppe; Naletova, Irina; Nicoletti, Vincenzo Giuseppe; Attanasio, Francesco; Rizzarelli, Enrico. (2015). Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity.. Journal of inorganic biochemistry, 142, 39-46. https://doi.org/10.1016/j.jinorgbio.2014.09.008
MLA
Tabbì, Giovanni, et al. "Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity.." Journal of inorganic biochemistry, 2015. https://doi.org/10.1016/j.jinorgbio.2014.09.008
RethinkPeptides
RethinkPeptides Research Database. "Semax, an ACTH4-10 peptide analog with high affinity for cop..." RPEP-02805. Retrieved from https://rethinkpeptides.com/research/tabbi-2015-semax-an-acth410-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.